About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
GBT - Global Blood Therape...| Previous Close | $43.50 | Open | $44.00 |
| Volume | 798.2K | Market Cap | 3.04B |
| Yield | Last Dividend |
| RBC Capital Stick to Their Buy Rating fo... | 02/25/21 |
| RBC Capital Stick to Their Buy Rating for Global Blood Therapeutics | |
| H.C. Wainwright Stick to Their Buy Ratin... | 02/25/21 |
| H.C. Wainwright Stick to Their Buy Rating for Global Blood Therapeutics | |
| Oppenheimer Stick to Their Buy Rating fo... | 01/18/21 |
| Oppenheimer Stick to Their Buy Rating for Global Blood Therapeutics | |
| pre-filled saline syringes market Top Pl... | 12/31/20 |
| The global pre-filled saline syringes market accounted to US$ 402.5 Mn in 2018 and is expected to grow at a CAGR of 7.2% during the forecast period 20... | |
| Morgan Stanley Stick to Their Hold Ratin... | 12/16/20 |
| Morgan Stanley Stick to Their Hold Rating for Global Blood Therapeutics | |
| Global Blood Therapeutics recruits a CHO... | 12/11/20 |
| As a kid, Kim Smith-Whitley picked up injured animals from Rock Creek Park and biked them home in cages she built with her grandfather. They were simp... | |
| Wedbush Stick to Their Buy Rating for Gl... | 12/11/20 |
| Wedbush Stick to Their Buy Rating for Global Blood Therapeutics | |
| US FDA Approves Guerbet's Optiray?? (Iov... | 12/03/20 |
| PRINCETON, N.J., Dec. 3, 2020 /PRNewswire/ -- Guerbet (GBT), a global leader in medical imaging, announced today that it received US Food and Drug Adm... | |
| Guerbet to Showcase its UNIK Solution at... | 11/12/20 |
| PRINCETON, N.J., Nov. 12, 2020 /PRNewswire/ -- Guerbet (GBT) a global leader in medical imaging, announced today that it will highlight UNIK, a tailor... | |
| Roth Capital Stick to Their Buy Rating f... | 11/08/20 |
| Roth Capital Stick to Their Buy Rating for Global Blood Therapeutics | |
| Global Blood Therapeutics, Inc. (NASDAQ:... | 11/07/20 |
| Global Blood Therapeutics, Inc. (NASDAQ:GBT) missed earnings with its latest quarterly results, disappointing??? | |
| Mid-Afternoon Market Update: Nasdaq Turn... | 11/06/20 |
| Toward the end of trading Friday, the Dow traded down 0.18% to 28,339.69 while the NASDAQ rose 0.16% to 11,910.11. The S&P also rose, gaining 0.03% to... | |
| Global Blood Therapeutics News: 5 Things... | 11/06/20 |
| Global Blood Therapeutics (GBT) news for Friday includes poor results from its third-quarter earnings report sending GBT stock lower. | |
| Global Blood Therapeutics Is it time to ... | 11/05/20 |
| Global Blood Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself b... | |
| Contrast Media Injectors Market 2020: Re... | 09/30/20 |
| Contrast Media Injectors Market Overview According to the newly published report by Reports and Data, the Contrast Media Injectors Market report prese... | |
| Why Global Blood Therapeutics Is Trading... | 08/25/20 |
| Global Blood Therapeutics (NASDAQ: GBT ) shares are trading higher on Tuesday after Raymond James initiated coverage on the company's stock with an Ou... | |
| Seattle Genetics Appoints Ted W. Love, M... | 08/18/20 |
| BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Ted W. Love, M.D., has been appointed to the company???s Bo... | |
| Global Blood Analyst Projects More Than ... | 07/01/20 |
| Shares of Global Blood Therapeutics Inc (NASDAQ: GBT ) have materially underperformed the broader biotech group, rendering its valuation attractive, a... | |
| Global Blood Therapeutics Up On Expanded... | 06/09/20 |
| Shares in Global Blood Therapeutics (GBT) rose 5% in Monday???s extended trading after the company announced plans to expand the potential use of ??? ... | |
| Global Diagnostic Substances Industry Re... | 05/28/20 |
| DUBLIN--(BUSINESS WIRE)--The "Diagnostic Substances (GLOBAL) - Industry Report" has been added to ResearchAndMarkets.com's offering. The Global Diagno... | |
| How Global Blood Therapeutics (GBT) Stoc... | 05/15/20 |
| Global Blood Therapeutics (GBT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. | |
| Global Blood Therapeutics Shows More Dow... | 03/04/20 |
| Global Blood Therapeutics Shows More Downside Risk Right Now???GBT | |
| Guerbet Announces Appointment of Thomas ... | 01/08/20 |
| PRINCETON, N.J., Jan. 8, 2020 /PRNewswire/ -- Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced today that ... | |
| Global Blood (GBT) Shares Double in a Ye... | 01/02/20 |
| Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in p... | |
| Global Blood Therapeutics and Syros Phar... | 12/18/19 |
| Global Blood Therapeutics Inc. and Syros Pharmaceuticals announced a partnership to develop and commercialize therapies for sickle cell disease and be... | |
| The Daily Biotech Pulse: Correvio Faces ... | 12/11/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) ... | |
| The Daily Biotech Pulse: ASH Meeting Wra... | 12/10/19 |
| The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acce... | |
| Tax Season 2020: Make Tax-Free Income on... | 12/08/19 |
| BMTC Group Inc is a buy-and-hold stock that???s ideal for your TFSA. Here is why you should buy it today. | |
| The Daily Biotech Pulse: Cassava Gains O... | 12/06/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) A... | |
| The Daily Biotech Pulse: Aurinia Rips Hi... | 12/05/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) A... | |
| Hold rating | 01/20/21 |
| Piper Sandler downgrades from Overweight to Neutral rating and lowers Price Target from $75.00 to $50.00 | |
| Hold rating | 12/16/20 |
| Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $67.00 to $45.00 | |
| Buy rating | 12/15/20 |
| and announces Price Target of $75.00 | |
| Strong Buy rating | 12/03/20 |
| RBC Capital initiates coverage with Outperform rating and announces Price Target of $75.00 | |
| Date | 2021-02-24 (AMC) | Est. (EPS/Rev.) | ($0.94)/ 39.03M |
| Actual (EPS/Rev.) | $-1.00/ $41.30 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Trading | Trading | 99.00 % | Follow |
| Optioneering-W | Sam Allen | 27.00 % | Follow |
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
